Related references
Note: Only part of the references are listed.Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
Regan M. Memmott et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study
Filipe Martins et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Current approaches to the management of brain metastases
John H. Suh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Systemic treatment of brain metastases in non-small cell lung cancer
Simon Page et al.
EUROPEAN JOURNAL OF CANCER (2020)
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
N. Vilarino et al.
CANCER TREATMENT REVIEWS (2020)
Management of brain metastases according to molecular subtypes
Riccardo Soffietti et al.
NATURE REVIEWS NEUROLOGY (2020)
Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality
Frank H. Annie et al.
PHARMACOTHERAPY (2020)
Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor
Saber Amin et al.
JAMA NETWORK OPEN (2020)
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Lucio Crino et al.
LUNG CANCER (2019)
The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
Rupesh Kotecha et al.
NEURO-ONCOLOGY (2019)
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Ronan Flippot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival
Anders W. Erickson et al.
FRONTIERS IN ONCOLOGY (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Evolving Landscape of Brain Metastasis
Manuel Valiente et al.
TRENDS IN CANCER (2018)
Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study
Courtney Kromer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Brain Metastases in Newly Diagnosed Breast Cancer A Population-Based Study
Allison M. Martin et al.
JAMA ONCOLOGY (2017)
Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto et al.
JAMA ONCOLOGY (2017)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Long-term survival with metastatic cancer to the brain
WA Hall et al.
MEDICAL ONCOLOGY (2000)
Share Paper
